OmniAb, Inc. (OABIW) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
OmniAb, Inc. (OABIW) trades at $0.2845. OmniAb, Inc. is a biotechnology company specializing in therapeutic antibody discovery technologies. Their OmniAb platform leverages genetically modified animals to generate human-sequence antibodies for next-generation therapeutics. Market cap: $1.81B, Sector: Healthcare.
Price as of Aug 21, 2026 · Last analyzed: Mar 16, 2026Analyst Coverage for OABIW: OABIW does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates OABIW against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
Not enough scored data yet to form a council read on OABIW.
How is this calculated? →OmniAb, Inc. (OABIW) Healthcare & Pipeline Overview
OmniAb, Inc. is a biotechnology company providing therapeutic antibody discovery technologies, utilizing its OmniAb platform of genetically modified animals to generate human-sequence antibodies. The company focuses on enabling partners to develop next-generation therapeutics, operating within the competitive biotechnology landscape.
What Is the Investment Thesis for OABIW?
OmniAb, Inc. presents a unique investment proposition within the biotechnology sector, driven by its innovative antibody discovery platform. The company's OmniAb platform, utilizing transgenic animals to generate human-sequence antibodies, offers a potential competitive advantage in the development of next-generation therapeutics. With a market capitalization of $1.81B and a negative P/E ratio of -3.53, the company's valuation reflects its current profitability challenges, indicated by a profit margin of -347.0%. However, a gross margin of 73.5% suggests potential for future profitability as the company scales its operations and secures additional partnerships. Key growth catalysts include expanding partnerships with pharmaceutical companies and advancing the development of therapeutics derived from its OmniAb platform. Potential risks include competition from other antibody discovery companies and the inherent uncertainty in drug development.
Based on FMP financials and quantitative analysis
OABIW Key Highlights
Gross Margin of 73.5% indicates strong potential profitability from its antibody discovery platform.
- Market Cap of $1.81B reflects the company's current valuation in the biotechnology market.
- Profit Margin of -347.0% highlights current challenges in achieving profitability.
- Beta of 0.85 suggests the stock is slightly less volatile than the overall market.
- The company's OmniAb platform offers a differentiated approach to antibody discovery, potentially attracting partnerships with pharmaceutical companies.
Who Are OABIW's Competitors?
OABIW is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| CGEN Compugen Ltd. | $2.65 | +8.61% | $251M | 76 |
| CHRS Coherus Oncology, Inc. | $1.32 | -0.75% | $204M | — |
| GNLX Genelux Corporation | $2.74 | +2.24% | $123M | — |
| HRTX Heron Therapeutics, Inc. | $0.31 | -1.87% | $58.5M | — |
| IVVD Invivyd, Inc. | $0.99 | +3.17% | $292M | — |
| GLPG Galapagos NV | $27.98 | +1.71% | $1.84B | 70 |
| ETON Eton Pharmaceuticals, Inc. | $59.91 | -2.55% | $1.64B | 98 |
| INVA Innoviva, Inc. | $21.04 | -2.05% | $1.55B | 94 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are OABIW's Key Strengths?
Proprietary OmniAb platform with unique transgenic animals.
- Diverse antibody repertoire and screening technologies.
- Established partnerships with pharmaceutical companies.
- Experienced management team with expertise in antibody discovery.
What Are OABIW's Weaknesses?
Negative profit margin indicates current challenges in achieving profitability.
- Reliance on partnerships for revenue generation.
- Small market capitalization may limit access to capital.
- Competition from established players in the antibody discovery market.
What Could Drive OABIW Stock Higher?
Expansion of partnerships with pharmaceutical companies to utilize the OmniAb platform for drug discovery.
- Advancement of internal therapeutic programs derived from the OmniAb platform.
- Publication of preclinical data demonstrating the efficacy of antibodies discovered using the OmniAb platform.
- Potential regulatory milestones for therapeutic candidates developed using OmniAb technology.
What Are the Key Risks for OABIW?
Competition from other antibody discovery companies with established platforms and technologies.
- Uncertainty in drug development and regulatory approval processes.
- Intellectual property disputes or challenges to the validity of OmniAb's patents.
- Dependence on partnerships for revenue generation and future growth.
- The company's negative profit margin poses a risk to its long-term financial sustainability.
What Are the Growth Opportunities for OABIW?
- Expanding Partnerships with Pharmaceutical Companies: OmniAb can drive growth by securing additional partnerships with pharmaceutical and biotechnology companies. These partnerships can provide revenue through licensing fees, milestone payments, and royalties on resulting therapeutics. Securing long-term partnerships with major pharmaceutical companies can provide a stable revenue stream and validate the effectiveness of the OmniAb platform. Timeline: Ongoing.
- Advancing Internal Therapeutic Programs: OmniAb can invest in developing its own pipeline of therapeutic candidates derived from its OmniAb platform. This approach can increase the company's value by generating clinical data and demonstrating the potential of its technology. The market for novel therapeutics is vast, with opportunities to address unmet medical needs in various disease areas. By advancing its own programs, OmniAb can potentially generate significant returns and attract further investment. Timeline: Ongoing.
- Leveraging OmniFlic and OmniClic for Bispecific Antibody Development: OmniAb's OmniFlic and OmniClic platforms offer unique capabilities for developing bispecific antibodies, which are gaining increasing attention in the industry. Bispecific antibodies can target two different antigens simultaneously, offering potential advantages in treating complex diseases. By focusing on bispecific antibody development, OmniAb can capitalize on this growing market segment and differentiate itself from competitors. Timeline: Ongoing.
- Expanding into New Geographic Markets: OmniAb can expand its operations into new geographic markets, such as Europe and Asia, to increase its customer base and revenue. These markets offer significant opportunities for growth, driven by increasing healthcare spending and a growing demand for innovative therapeutics. By establishing a presence in new markets, OmniAb can diversify its revenue streams and reduce its reliance on the US market. Timeline: Ongoing.
- Developing New Transgenic Animal Platforms: OmniAb can continue to invest in research and development to create new transgenic animal platforms with enhanced capabilities for antibody discovery. This can provide the company with a competitive advantage by offering unique solutions that are not available from other providers. The market for antibody discovery technologies is constantly evolving, and companies that can innovate and develop new solutions will be well-positioned for long-term success. Timeline: Ongoing.
What Are OABIW's Competitive Advantages?
- Proprietary transgenic animal platforms (OmniRat, OmniChicken, OmniMouse) provide a unique source of human-sequence antibodies.
- Extensive antibody repertoire and screening technologies offer a competitive advantage in antibody discovery.
- Established partnerships with pharmaceutical and biotechnology companies create a barrier to entry for new competitors.
- Intellectual property protection for its transgenic animal platforms and antibody discovery technologies.
What Does OABIW Do?
Founded in 2012 and headquartered in Emeryville, California, OmniAb, Inc. is a biotechnology company focused on providing innovative therapeutic antibody discovery technologies. The company's core offering is the OmniAb platform, which utilizes proprietary transgenic animals, including OmniRat, OmniChicken, and OmniMouse. These animals are genetically modified to produce antibodies with human sequences, streamlining the development of human therapeutic candidates. OmniAb's platform aims to provide industry partners with access to diverse antibody repertoires and advanced screening technologies, facilitating the discovery of novel therapeutics. The company's portfolio also includes OmniFlic and OmniClic, designed for bispecific antibody applications, and OmniTaur, which leverages the unique structural attributes of cow antibodies for targeting complex antigens. OmniAb's business model centers around partnering with pharmaceutical and biotechnology companies, providing them with access to its antibody discovery platform and technologies to accelerate their drug development programs. The company operates primarily in the United States.
What Products and Services Does OABIW Offer?
- Provides therapeutic antibody discovery technologies to industry partners.
- Offers access to diverse antibody repertoires and screening technologies.
- Enables the discovery of next-generation therapeutics.
- Utilizes the OmniAb platform, featuring genetically modified animals.
- Generates antibodies with human sequences to facilitate development of human therapeutic candidates.
- Offers OmniFlic and OmniClic for bispecific antibody applications.
- Provides OmniTaur that features unique structural attributes of cow antibodies for complex targets.
How Does OABIW Make Money?
- Partnerships with pharmaceutical and biotechnology companies.
- Licensing fees for access to the OmniAb platform.
- Milestone payments based on the progress of drug development programs.
- Royalties on sales of therapeutics developed using the OmniAb platform.
What Industry Does OABIW Operate In?
OmniAb, Inc. operates within the competitive biotechnology industry, which is characterized by rapid innovation and significant investment in research and development. The market for antibody discovery technologies is driven by the increasing demand for novel therapeutics and the growing prevalence of chronic diseases. Companies like OmniAb face competition from established players and emerging startups, all vying to develop innovative solutions for drug discovery. The biotechnology industry is experiencing steady growth, fueled by advancements in genomics, proteomics, and other related fields. OmniAb's focus on leveraging transgenic animals for antibody discovery positions it within a niche segment of the broader biotechnology market.
Who Are OABIW's Key Customers?
- Pharmaceutical companies seeking to discover and develop new antibody therapeutics.
- Biotechnology companies focused on developing innovative therapies.
- Research institutions conducting antibody discovery research.
Company Profile
OmniAb, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in EmeryVille, US. The company is led by CEO Matthew W. Foehr. OABIW has traded publicly since 2021.
Financial Health
OmniAb, Inc.'s Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 4.77 places it in the safe zone, indicating low near-term bankruptcy risk.
Forward Outlook
Wall Street analysts project OmniAb, Inc. revenue of about $30.8M for fiscal 2026, with EPS near $-0.41. The estimate reflects 7 contributing analysts.
OABIW Financials
Bull Case vs Bear Case
Bull Case
- Proprietary OmniAb platform with unique transgenic animals.
- Diverse antibody repertoire and screening technologies.
- Established partnerships with pharmaceutical companies.
- Experienced management team with expertise in antibody discovery.
Bear Case
- Negative profit margin indicates current challenges in achieving profitability.
- Reliance on partnerships for revenue generation.
- Small market capitalization may limit access to capital.
- Competition from established players in the antibody discovery market.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · August 2026
OABIW Latest News
No recent news available for OABIW.
OABIW Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for OABIW.
Price Targets
Wall Street price target analysis for OABIW.
OABIW MoonshotScore
What does this score mean?
The MoonshotScore rates OABIW 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Matthew W. Foehr
CEO
Matthew W. Foehr serves as the CEO of OmniAb, Inc., bringing extensive experience in the biotechnology industry. His background includes leadership roles in various pharmaceutical and biotechnology companies, where he focused on strategic planning, business development, and commercialization of innovative therapies. Foehr's expertise spans across multiple therapeutic areas, including oncology, immunology, and infectious diseases. He holds advanced degrees in science and business, providing him with a strong foundation in both the scientific and commercial aspects of the biotechnology industry.
Track Record: Under Matthew W. Foehr's leadership, OmniAb, Inc. has focused on expanding its partnerships with pharmaceutical companies and advancing the development of its OmniAb platform. Key achievements include securing collaborations with major pharmaceutical players and generating preclinical data demonstrating the potential of its antibody discovery technologies. Foehr has also overseen the company's efforts to expand its intellectual property portfolio and strengthen its competitive position in the antibody discovery market.
OABIW Healthcare Stock FAQ
What does OmniAb, Inc. do?
OmniAb, Inc. is a biotechnology company that provides therapeutic antibody discovery technologies to pharmaceutical and biotechnology companies. The company's core offering is the OmniAb platform, which utilizes genetically modified animals to generate human-sequence antibodies. These antibodies can then be used by partners to develop novel therapeutics for a wide range of diseases.
What are the main risks for OABIW?
The main risks for OmniAb, Inc. include competition from other antibody discovery companies, uncertainty in drug development and regulatory approval, potential intellectual property disputes, and dependence on partnerships for revenue generation. The company's negative profit margin also poses a risk to its long-term financial sustainability. Investors should carefully consider these risks before investing in OABIW.
How does OmniAb, Inc.'s technology compare to traditional antibody discovery methods?
OmniAb, Inc.'s technology offers several advantages over traditional antibody discovery methods. The OmniAb platform utilizes genetically modified animals to generate antibodies with human sequences, which can reduce the risk of immunogenicity in humans. The platform also allows for the generation of a diverse range of antibodies, increasing the chances of finding a therapeutic candidate with the desired properties.
What is OmniAb, Inc.'s strategy for protecting its intellectual property?
OmniAb, Inc. employs a multi-faceted strategy for protecting its intellectual property. This includes securing patents for its transgenic animal platforms, antibody sequences, and antibody discovery technologies. The company also relies on trade secrets to protect confidential information and know-how. OmniAb actively monitors the competitive landscape for potential intellectual property infringement and takes appropriate action to enforce its rights.
What are the key factors to evaluate for OABIW?
Evaluate OABIW on fundamentals, analyst consensus, and risk factors. OmniAb, Inc. presents a unique investment proposition within the biotechnology sector, driven by its innovative antibody discovery platform. Not financial advice.
How frequently does OABIW data refresh on this page?
OABIW's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven OABIW's recent stock price performance?
OmniAb, Inc. (OABIW) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary OmniAb platform with unique transgenic animals. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider OABIW overvalued or undervalued right now?
OmniAb, Inc. (OABIW) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- AI analysis pending, which may provide further insights.
- Financial data based on available information as of 2026-03-16.